ClinicalTrials.gg
RecruitingNCT07381374Updated Jun 9, 2026

Fecal Microbiota Transplantation in Children With ASD

An interventional study of ctive FMT via Nasojejunal Tube (FMT-Upper GI) and Active FMT via Colonoscopy and Transendoscopic Tube (FMT-Lower GI) in Autism Spectrum Disorder, sponsored by Shenzhen Children's Hospital. Recruiting at 1 site in China. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Shenzhen Children's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
3 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Autism Spectrum Disorder with a site in China — 37 open to participants now, 38 under way, none of them phase 3. Autism Spectrum Disorder · China.

Planned enrollment
62nd of 63
1 · median 96
Started
2026
with 7 others
No phase
50 of 86
21 open now
Primary completion
2026-12
later than 18 of 37 live
Registered
73rd of 86
by date

Among the 86 studies in Autism Spectrum Disorder with a site in China, this one is the 62nd largest by planned enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2026, is one of 50 with no phase, reaches primary completion later than 18 of the 37 other live ones, and was the 73rd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

37 of the 86 studies in Autism Spectrum Disorder with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 3 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Autism Spectrum Disorder with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-dummy, triple-blind, placebo-controlled, three-arm parallel-group superiority trial. The study aims to compare the efficacy and safety of Fecal Microbiota Transplantation (FMT) administered via two different invasive routes-nasojejunal tube (NJT) and colonoscopy-versus a placebo control in children aged 3-16 years with moderate-to-severe Autism Spectrum Disorder (ASD). A total of 75 participants will be randomized in a 1:1:1 ratio to receive either active FMT via NJT with sham colonoscopy, active FMT via colonoscopy with sham NJT, or placebo via both routes. All participants will continue their stable behavioral interventions throughout the study. The primary outcome is the change from baseline to Week 24 in the total score of the Childhood Autism Rating Scale (CARS). Secondary outcomes include changes in other behavioral and gastrointestinal symptom scores, gut microbiota profiling, and safety assessments over 48 weeks.

Read the detailed description

Background:

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder often accompanied by gastrointestinal (GI) symptoms and gut microbiota dysbiosis. Fecal Microbiota Transplantation (FMT) has shown promise in modulating the gut-brain axis and improving both behavioral and GI symptoms in preliminary ASD studies. However, the optimal route of FMT administration remains unclear, and high-quality comparative evidence is lacking.

Objectives:

Primary: To compare the efficacy of FMT delivered via NJT versus colonoscopy versus placebo in improving social interaction and communication, as measured by the change in CARS total score from baseline to Week 24.

Secondary: To evaluate effects on social responsiveness (SRS), aberrant behaviors (ABC), sensory processing (SSP), sleep quality (CSHQ), GI symptoms (GSRS), gut microbiota engraftment dynamics, and safety/tolerability.

Methods:

Design: Single-center, randomized, double-dummy, triple-blind, placebo-controlled, three-arm parallel-group trial.

Participants: 75 children aged 3-16 years with DSM-5-confirmed moderate-to-severe ASD (CARS ≥36) and stable behavioral intervention.

Interventions:

Group 1 (FMT-NJT): Active FMT via NJT + sham colonoscopy. Group 2 (FMT-C): Active FMT via colonoscopy with placement of a transendoscopic enteral tube (TET) in the cecum for subsequent infusions + sham NJT.

Group 3 (Control): Placebo via both NJT and colonoscopy (sham procedures). Dosage: 5 mL/kg (max 100 mL) per infusion, administered every other day for three sessions.

Blinding: Triple-blind-participants/guardians, outcome assessors, and data analysts are blinded. An independent pharmacy unit prepares identical active and placebo preparations.

Assessments: Behavioral scales (CARS-2, SRS-2, ABC, SSP, CSHQ), GI symptoms (GSRS), stool metagenomics, and safety monitoring at baseline, Weeks 2, 6, 12, 24, and 48.

Sample Size: 25 per group (total N=75), calculated to detect a 2.5-point difference in CARS change with 80% power, accounting for 15% dropout.

Randomization: Centralized block randomization stratified by age and baseline CARS severity.

Statistical Analysis: ANCOVA for primary outcome with baseline adjustment; mixed models for repeated measures; descriptive and inferential methods for secondary and safety outcomes.

Outcomes:

Primary: Change in CARS-2 total score from baseline to Week 24. Secondary: Changes in SRS-2, ABC, GSRS, SSP, CSHQ scores; microbiota composition/function; incidence and severity of adverse events (CTCAE v5.0).

Significance: This trial will provide high-level evidence on whether the therapeutic effect of FMT in ASD depends on the gastrointestinal delivery site. The novel TET-based protocol for repeated cecal delivery allows for a rigorous comparison of microbial engraftment in the lower versus upper GI tract. The results will guide the optimization of microbiota-targeted therapies for ASD and other conditions linked to the gut-brain axis.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism Spectrum Disorder
  • Fecal Microbiota Transplantation
  • Microbiome
  • children
04

Who can participate

Ages eligible
3 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 3-16 years.
  • Diagnosed with ASD according to the , Fifth Edition (DSM-5), with a Childhood Autism Rating Scale (CARS) total score ≥36 (moderate-to-severe autism).
  • Legal guardians fully comprehend the trial's and voluntarily provide written consent.
  • Compliance with follow-up visits, examinations, and specimen collection.
  • No probiotic supplements consumed within the preceding 3 months.

Exclusion criteria

Exclusion Criteria:

  • Use of probiotics or prebiotics within 3 months prior to enrollment.
  • Antibiotic usage within 1 month prior to enrollment.
  • Presence of fever (axillary temperature ≥37.5°C).
  • Dependency on tube feeding.
  • Severe gastrointestinal conditions requiring immediate intervention (e.g., life-threatening intestinal obstruction, perforation, hemorrhage, ulcerative colitis, Crohn's disease, celiac disease, or eosinophilic esophagitis).
  • Diagnosis of severe malnutrition, underweight status (-for-age \<3rd percentile), or severe immunodeficiency disorders.
  • History of severe allergic reactions (e.g., anaphylaxis).
  • Monogenic disorders (e.g., Fragile X syndrome, Rett syndrome).
  • Comorbid psychiatric diagnoses, including depression, developmental speech/language disorders, intellectual disability, attention-deficit/hyperactivity disorder (ADHD), selective mutism, reactive attachment disorder, or childhood schizophrenia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (estimated)

Study arms

  • Active comparator
    Group 1 (FMT-NJT)

    active FMT via nasojejunal tube + sham colonoscopy

    Procedure: ctive FMT via Nasojejunal Tube (FMT-Upper GI)

  • Active comparator
    Group 2 (FMT-C)

    active FMT via colonoscopy with placement of a transendoscopic enteral tube (TET) secured at the cecum during the first session, followed by two subsequent infusions via the indwelling TET + sham nasojejunal intubation.

    Procedure: Active FMT via Colonoscopy and Transendoscopic Tube (FMT-Lower GI)

  • Placebo comparator
    Group 3 (Control)

    placebo via nasojejunal tube + placebo via colonoscopy (sham procedures for both routes)

    Procedure: Placebo via Sham Procedures (Sham-Control)

Interventions

  • Procedurective FMT via Nasojejunal Tube (FMT-Upper GI)

    Intervention: Active FMT via Nasojejunal Tube (FMT-Upper GI) Intervention Type: Procedure + Biological Intervention Name: Upper Gastrointestinal-Targeted Fecal Microbiota Transplantation Description: Participants in this group receive active fecal microbiota suspension delivered to the jejunum (upper gastrointestinal tract). Under endoscopic guidance, a nasojejunal tube is placed with its tip positioned past the Ligament of Treitz. The active FMT preparation is then infused slowly through this tube. Additionally, participants undergo a sham colonoscopy (simulated procedure under anesthesia where the scope is inserted to the rectosigmoid junction with minimal water/air insufflation, but no FMT is administered). Dosage: 5 mL per kilogram of body weight, with a maximum total volume of 100 mL per infusion. Frequency: Administered once every other day, for a total of three sessions over 5 days.

  • ProcedureActive FMT via Colonoscopy and Transendoscopic Tube (FMT-Lower GI)

    Participants in this group receive active fecal microbiota suspension delivered to the cecum (lower gastrointestinal tract). The intervention involves two phases: First Session (Day 0): Under general anesthesia, a full colonoscopy is performed to reach the cecum. The active FMT preparation is infused directly into the cecum. Subsequently, a transendoscopic enteral tube (TET) is advanced through the colonoscope and its tip is secured in the cecum using endoscopic clips. Second \& Third Sessions (Days 2 \& 4): The active FMT preparation is infused through the indwelling TET at the bedside, without the need for repeat colonoscopy or general anesthesia. Additionally, participants undergo a sham nasojejunal intubation (a tube is placed into the stomach and secured, and a placebo is infused). Dosage: 5 mL per kilogram of body weight, with a maximum total volume of 100 mL per infusion. Frequency: Administered once every other day, for a total of three sessions over 5 days.

  • ProcedurePlacebo via Sham Procedures (Sham-Control)

    Participants in this control group undergo both sham procedures with infusion of an inactivated placebo suspension, which is visually and physically identical to the active FMT preparation but contains no viable microbiota. Sham Nasojejunal Intubation: A tube is placed into the stomach (not the jejunum) and secured. The placebo suspension is infused. Sham Colonoscopy: Under anesthesia, a simulated colonoscopy is performed (scope inserted to rectosigmoid junction with minimal insufflation). No substance is infused during this sham procedure. This double-sham design ensures that both potential delivery routes are "simulated" for the control group. Dosage: Volume-matched to the active FMT arms (5 mL/kg, max 100 mL) for the nasogastric infusion. No infusion during sham colonoscopy. Frequency: The placebo infusion (during sham NJ intubation) occurs once every other day, for a total of three sessions over 5 days, coinciding with the two sham procedures.

06

What researchers measure

Primary outcomes

  1. Change in Total Score on the Childhood Autism Rating Scale (CARS)

    The change from baseline to Week 24 in the total score of the Childhood Autism Rating Scale (CARS). The CARS is a 15-item behavioral rating scale used to diagnose and assess the severity of autism. Each item is scored from 1 to 4. The total score ranges from 15 to 60. A higher score indicates more severe autism symptoms.

    Time frame: Pre-FMT, 3 months post-FMT, and 6 months post-FMT

Secondary outcomes

  1. Change in Total Score on the Social Responsiveness Scale, Second Edition (SRS-2)

    Change from baseline to Weeks 12, 24, and 48. The SRS-2 assesses social impairments associated with autism spectrum disorders. Raw scores are converted to T-scores. Higher T-scores indicate greater severity of social impairment.

    Time frame: Pre-FMT, at Week 12, 24, and 48 post-FMT.

  2. Change in Total Score on the Aberrant Behavior Checklist (ABC)

    Change from baseline to Weeks 12, 24, and 48. The ABC assesses problem behaviors in individuals with developmental disabilities. Higher scores indicate more severe problem behaviors.

    Time frame: Pre-FMT, at Week 12, 24, and 48 post-FMT.

  3. Change in Total Score on the Gastrointestinal Symptom Rating Scale (GSRS)

    Change from baseline to Weeks 2, 6, 12, 24, and 48. The GSRS evaluates common gastrointestinal symptoms. Each item is scored from 1 (no discomfort) to 7 (very severe discomfort). Higher scores indicate worse GI symptoms.

    Time frame: Pre-FMT, during FMT, and at 2, 6, 12, 24, and 48 post-FMT.

  4. Daily Stool Record (DSR)

    Daily documentation of stool characteristics using the Bristol Stool Scale. The percentage of days with abnormal bowel movements (e.g., abnormal consistency, absence of stool, or use of GI medications) is calculated, with higher percentages indicating worse symptoms.

    Time frame: Pre-FMT, during FMT, and at 2, 6, 12, 24 and 48 weeks post-FMT.

  5. Change in Total Score on the Short Sensory Profile (SSP)

    Change from baseline to Weeks 12, 24, and 48. The SSP measures sensory processing patterns in children. Lower scores indicate greater sensory processing difficulties.

    Time frame: Pre-FMT, at12, 24 and 48 post-FMT.

  6. Change in Total Score on the Children's Sleep Habits Questionnaire (CSHQ)

    Change from baseline to Weeks 12, 24, and 48. The CSHQ assesses sleep problems in children. Higher scores indicate more disturbed sleep.

    Time frame: Pre-FMT, at12, 24 and 48 post-FMT.

  7. Change in Gut Microbiota Alpha Diversity (Shannon Index)

    Change from baseline to Weeks 2, 6, 12, 24, and 48 as measured by shotgun metagenomic sequencing. Alpha diversity measures the richness and evenness of microbial species within a sample.

    Time frame: Pre-FMT, and at 2, 6, 12, 24 and 48 weeks post-FMT.

  8. Change in Relative Abundance of Specific Gut Microbial Taxa (at the genus level)

    Change from baseline to Weeks 2, 6, 12, 24, and 48 as measured by shotgun metagenomic sequencing (e.g., using MetaPhlAn for taxonomic profiling).

    Time frame: Pre-FMT, and at 2, 6, 12, 24 and 48 weeks post-FMT.

  9. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    The number and percentage of participants experiencing any adverse event during the study period, graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. The relationship to the study intervention (FMT/placebo procedures) will be assessed by the investigator.

    Time frame: From date of randomization until the end of study visit (Week 48).

  10. Incidence of Serious Adverse Events (SAEs)

    The number and percentage of participants experiencing any serious adverse event during the study period, as defined by CTCAE v4.0 and ICH guidelines.

    Time frame: From date of randomization until the end of study visit (Week 48).

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital, Shenzhen
    Shenzhen, Guangdong 518026, China
    Recruiting
08

References and documents

Publications

  • Ghirardini A, Nanni-Costa A, Venturi S, Ridolfi L, Petrini F, Taddei S, Venturoli A, Pugliese MR, Monti M, Martinelli G. Efficiency of organ procurement and transplantation programs. Transpl Int. 2000;13 Suppl 1:S267-71. doi: 10.1007/s001470050339. PubMed 11112010 ↗
  • Li Y, Xiao P, Ding H, Wang H, Xu Q, Wang R, Zheng L, Song X, Wang Y, Zhang T. Fecal Microbiota Transplantation in Children with Autism. Neuropsychiatr Dis Treat. 2024 Dec 9;20:2391-2400. doi: 10.2147/NDT.S488001. eCollection 2024. PubMed 39677507 ↗
  • Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, Khoruts A, Geis E, Maldonado J, McDonough-Means S, Pollard EL, Roux S, Sadowsky MJ, Lipson KS, Sullivan MB, Caporaso JG, Krajmalnik-Brown R. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017 Jan 23;5(1):10. doi: 10.1186/s40168-016-0225-7. PubMed 28122648 ↗
  • Chen K, Fu Y, Wang Y, Liao L, Xu H, Zhang A, Zhang J, Fan L, Ren J, Fang B. Therapeutic Effects of the In Vitro Cultured Human Gut Microbiota as Transplants on Altering Gut Microbiota and Improving Symptoms Associated with Autism Spectrum Disorder. Microb Ecol. 2020 Aug;80(2):475-486. doi: 10.1007/s00248-020-01494-w. Epub 2020 Feb 26. PubMed 32100127 ↗
  • Flora SJ, Tripathi N. Hepatic and renal metallothionein induction following single oral administration of gallium arsenide in rats. Biochem Mol Biol Int. 1998 Sep;45(6):1121-7. doi: 10.1080/15216549800203342. PubMed 9762410 ↗
  • Tan Q, Orsso CE, Deehan EC, Kung JY, Tun HM, Wine E, Madsen KL, Zwaigenbaum L, Haqq AM. Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review. Autism Res. 2021 Sep;14(9):1820-1836. doi: 10.1002/aur.2560. Epub 2021 Jun 26. PubMed 34173726 ↗
  • Goncalves CL, Doifode T, Rezende VL, Costa MA, Rhoads JM, Soutullo CA. The many faces of microbiota-gut-brain axis in autism spectrum disorder. Life Sci. 2024 Jan 15;337:122357. doi: 10.1016/j.lfs.2023.122357. Epub 2023 Dec 19. PubMed 38123016 ↗
  • Ullah H, Arbab S, Tian Y, Chen Y, Liu CQ, Li Q, Li K. Crosstalk between gut microbiota and host immune system and its response to traumatic injury. Front Immunol. 2024 Jul 31;15:1413485. doi: 10.3389/fimmu.2024.1413485. eCollection 2024. PubMed 39144142 ↗
  • Njeh CF, Fuerst T, Diessel E, Genant HK, Hausler KD. Association between QUS and structural parameters? Calcif Tissue Int. 2000 Sep;67(3):273-4. doi: 10.1007/s002230001136. No abstract available. PubMed 10954784 ↗
  • Ullah H, Arbab S, Tian Y, Liu CQ, Chen Y, Qijie L, Khan MIU, Hassan IU, Li K. The gut microbiota-brain axis in neurological disorder. Front Neurosci. 2023 Aug 4;17:1225875. doi: 10.3389/fnins.2023.1225875. eCollection 2023. PubMed 37600019 ↗
  • Morton JT, Jin DM, Mills RH, Shao Y, Rahman G, McDonald D, Zhu Q, Balaban M, Jiang Y, Cantrell K, Gonzalez A, Carmel J, Frankiensztajn LM, Martin-Brevet S, Berding K, Needham BD, Zurita MF, David M, Averina OV, Kovtun AS, Noto A, Mussap M, Wang M, Frank DN, Li E, Zhou W, Fanos V, Danilenko VN, Wall DP, Cardenas P, Baldeon ME, Jacquemont S, Koren O, Elliott E, Xavier RJ, Mazmanian SK, Knight R, Gilbert JA, Donovan SM, Lawley TD, Carpenter B, Bonneau R, Taroncher-Oldenburg G. Multi-level analysis of the gut-brain axis shows autism spectrum disorder-associated molecular and microbial profiles. Nat Neurosci. 2023 Jul;26(7):1208-1217. doi: 10.1038/s41593-023-01361-0. Epub 2023 Jun 26. PubMed 37365313 ↗
  • You M, Chen N, Yang Y, Cheng L, He H, Cai Y, Liu Y, Liu H, Hong G. The gut microbiota-brain axis in neurological disorders. MedComm (2020). 2024 Jul 20;5(8):e656. doi: 10.1002/mco2.656. eCollection 2024 Aug. PubMed 39036341 ↗
  • O'Brien CP, Testa T, O'Brien TJ, Greenstein R. Conditioning in human opiate addicts. Pavlov J Biol Sci. 1976 Oct-Dec;11(4):195-202. doi: 10.1007/BF03000314. PubMed 995439 ↗
  • Kodak T, Bergmann S. Autism Spectrum Disorder: Characteristics, Associated Behaviors, and Early Intervention. Pediatr Clin North Am. 2020 Jun;67(3):525-535. doi: 10.1016/j.pcl.2020.02.007. Epub 2020 May 4. PubMed 32443991 ↗
  • Penel C, Greppin H. Binding of plant isoperoxidases to pectin in the presence of calcium. FEBS Lett. 1994 Apr 18;343(1):51-5. doi: 10.1016/0014-5793(94)80605-5. PubMed 8163016 ↗
  • Sundkvist T. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Combining thromboembolic events with cardiovascular events does not support odds ratio of 0.7. BMJ. 1997 Sep 13;315(7109):677. No abstract available. PubMed 9310578 ↗
  • Senti M, Puig JM, Lloveras J, Aubo C, Mir M, Barbosa F, Oliveras A, Masramon J. Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients. Transplant Proc. 1997 Aug;29(5):2404-5. doi: 10.1016/s0041-1345(97)00421-1. No abstract available. PubMed 9270782 ↗
  • Bentele MJ, Vig KW, Shanker S, Beck FM. Efficacy of training dental students in the index of orthodontic treatment need. Am J Orthod Dentofacial Orthop. 2002 Nov;122(5):456-62. doi: 10.1067/mod.2002.126895. PubMed 12439472 ↗
  • Hirota T, King BH. Autism Spectrum Disorder: A Review. JAMA. 2023 Jan 10;329(2):157-168. doi: 10.1001/jama.2022.23661. PubMed 36625807 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Date for public release of raw data: within no later than 3 years after the publication of research results.

Access criteria: To download data, contact must be made with the researcher.

Data sharing details ↗ · www.medresman.org.cn

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 9 months is below that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2026
First posted
Feb 2, 2026
StartActual
Mar 21, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 12, 2027
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07381374
Lead sponsor
Shenzhen Children's Hospital
Collaborators
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences, Shenzhen Medical Academy of Research and Translation
Responsible party
Dongling Dai (Professor, Shenzhen Children's Hospital) — Principal investigator
First posted
Feb 2, 2026
Start date
Mar 21, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 12, 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

Dongling Dai, PhD
Contact
daidong3529@email.szu.edu.cn
08618938690736

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion